APP Pharmaceuticals and Fresenius Announce Clearance of APP Acquisition by U.S. Federal...

APP Pharmaceuticals and Fresenius Announce Clearance of APP Acquisition by U.S. Federal Trade Commission

SCHAUMBURG, Ill. & BAD HOMBURG V.D.H., Germany--(Business Wire)--
APP Pharmaceuticals, Inc. (Nasdaq:APPX) and Fresenius SE
(XETRA:FRE) have received confirmation that the U.S. Federal Trade
Commission (FTC) has completed its review of the proposed acquisition
of APP Pharmaceuticals by Fresenius Kabi, a business segment of
Fresenius SE. The FTC granted early termination of the waiting period
under the Hart-Scott-Rodino Act without conditions. The German
antitrust authorities had already approved the acquisition.

On July 7, 2008, Fresenius had announced the acquisition of APP
Pharmaceuticals, an important step in the growth strategy of Fresenius
Kabi. With the FTC review complete, Fresenius and APP expect the
transaction to close mid September 2008, subject to certain other
customary closing conditions.

About Fresenius SE

Fresenius is a health care group with international operations,
providing products and services for dialysis, hospital and outpatient
medical care. In 2007, group sales were approximately EUR 11.4
billion. On June 30, 2008 the Fresenius Group had 117,453 employees
worldwide. For more information visit the Company's website at
www.fresenius.com.

About Fresenius Kabi

Fresenius Kabi is the leader in infusion therapy and clinical
nutrition in Europe and in its most important countries of Latin
America and Asia Pacific. Fresenius Kabi's core product range includes
infusion solutions for fluid substitution, blood volume expansion and
parenteral nutrition, as well as products for enteral nutrition.
Furthermore, the company provides concepts for ambulatory health care
and is focused on managing and providing home therapies. With its
philosophy "Caring for life" and a comprehensive product portfolio,
the company aims at improving the quality of life of patients all over
the world. On June 30, 2008 the company had 18,323 employees. In 2007,
Fresenius Kabi achieved sales of EUR 2,030 million and an operating
profit of EUR 332 million. Fresenius Kabi AG is a 100 % subsidiary of
the health care group Fresenius SE.

About APP Pharmaceuticals, Inc.

APP is a fully-integrated pharmaceutical company that develops,
manufactures and markets injectable pharmaceutical products with a
primary focus on the oncology, anti-infective, anesthetic/analgesic
and critical care markets. The Company offers one of the most
comprehensive product portfolios used in hospitals, long-term care
facilities, alternate care sites and clinics within North America and
manufactures a comprehensive range of dosage formulations.

Forward-Looking Statement

The statements contained in this news release that are not purely
historical are forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements in this news release include statements
regarding the result of the review of the transaction by various
regulatory agencies; satisfaction of various conditions to the closing
of the transaction; existing and possible future litigation relating
to the transaction, our expectations, beliefs, hopes, goals,
intentions, initiatives or strategies. Because these forward-looking
statements involve risks and uncertainties, there are important
factors that could cause actual results to differ materially from
those in the forward-looking statements. These factors include, but
are not limited to, the availability and pricing of ingredients used
in the manufacture of pharmaceutical products and the ability to
successfully manufacture products in a time-sensitive and cost
effective manner. Additional relevant information concerning risks can
be found in the APP, Inc. Form10-K for the year ended December 31,
2007 and other documents the company has filed with the Securities and
Exchange Commission.

In connection with the proposed merger, Fresenius Kabi
Pharmaceuticals Holding, Inc. and APP have filed relevant materials
with the SEC, including a registration statement that contains a joint
prospectus and information statement. Investors and security holders
are urged to read these documents and any other relevant documents
filed with the SEC, as well as any amendments or supplements to those
documents, because they contain important information. Investors and
security holders may obtain these documents free of charge at the
SEC's website at www.sec.gov. Investors and security holders are urged
to read the joint information statement/prospectus and the other
relevant materials before making any investment decision with respect
to the proposed merger.

The information contained in this news release is as of the date
of this release. Neither Fresenius nor APP assume any obligation to
update any forward-looking statements contained in this press release
as the result of new information or future events or developments.

Investor and Media Inquiries:
APP Pharmaceuticals, Inc.
Maili Bergman
Director, Investor Relations
310-405-7522
or
PondelWilkinson Inc.
Robert Jaffe
310-279-5969
or
Fresenius SE
Investor Inquiries:
Fresenius SE
Birgit Grund
Senior Vice President
++49 6172 608 2485
or
Media Inquiries:
Fresenius SE
Joachim Weith
Senior Vice President
++49 6172 608 2101

Copyright Business Wire 2008